Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.
University of Würzburg, Würzburg, Germany.
Enno
E
Schmidt
Sandrine
S
Benoit
Eva-Bettina
EB
Bröcker
Detlef
D
Zillikens
Matthias
M
Goebeler
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D001706:Biopsy; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy* / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged; D000069283:Rituximab; D012867:Skin / Q000473:pathology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab